Roche won't boost Illumina offer without negotiating; OptiMedica gets good news in EU on Catalys;

@FierceMedDev: Siemens Manufacturing Plant Leaning Towards Collaboration With NHS Delegation. Item | Follow @FierceMedDev

> Roche ($RHHBY) says it would consider any argument to boost its $6.7 billion offer for Illumina ($ILMN) if the company would start negotiating, but has no plans to do so otherwise. Release

> Sunnyvale, CA-based OptiMedica has received CE Mark approval for its Catalys precision laser system for creating single-plane and multi-plane arc cuts/incisions in the cornea during cataract surgery. OptiMedica release

> Rosetta Genomics, a maker of microRNA-based molecular diagnostics, raised $1.38 million in a registered direct offering. The company plans to use the funds for "general corporate purposes." Release

> Optos has tapped Financial Times Group financial director Louisa Burdett as its next CFO. Her name may be familiar, as she played a key role during the merger of Glaxo and SmithKline. She also has served as CFO at General Electric Healthcare's medical diagnostics business. News

> 3M's Infection Prevention Division will team up with Sage Products to offer surgical staff and patients a new preoperative prepping kit to help address surgical site infection risk within three main reservoirs of bacteria. 3M release

> Novian Health has begun a multicenter clinical trial for Novilase interstitial laser therapy in malignant breast tumors. Novilase ILT is an image-guided, minimally invasive alternative for lumpectomy. Release

And Finally... A woman is suing Wright Medical after her hip joint replacement allegedly popped out of its socket and caused further damage to her leg. Article